Boston Scientific (BSX): Should You Buy, Sell, or Keep After Q4 Results?

Boston Scientific's Challenging Half-Year

Boston Scientific has endured a tough six months, with its share price tumbling 29% to $76.39. This sharp decline has unsettled many investors, prompting them to reconsider their investment strategies.

Is this downturn an opportunity to invest in BSX?

What Makes BSX a Hot Topic?

Established in 1979, Boston Scientific (NYSE:BSX) is dedicated to advancing minimally invasive medicine. The company designs and produces medical devices used in procedures across cardiovascular, urological, neurological, and gastrointestinal fields.

Key Strengths of Boston Scientific

1. Strong Performance in Core Operations

For those tracking diversified medical device companies, monitoring organic revenue is crucial. Unlike reported revenue, organic revenue excludes factors like mergers, acquisitions, divestitures, and currency changes, offering a clearer view of the company's fundamental business.

Boston Scientific has achieved an average annual organic revenue growth of 16.6% over the past two years. This robust growth demonstrates the company’s ability to expand rapidly without depending on costly and risky acquisitions.

2. Improved Free Cash Flow Margin Boosts Financial Health

Free cash flow is a key metric for evaluating a company’s financial strength. Ultimately, cash flow is what sustains a business, not just accounting profits.

Boston Scientific’s free cash flow margin has grown by 7 percentage points over the past five years. This indicates the company has become less reliant on capital, as its free cash flow profitability has outpaced operating profitability. Over the last twelve months, its free cash flow margin stood at 18.2%.

Potential Concern

Mixed Results from Previous Growth Strategies

Growth is important, but how efficiently a company achieves it matters just as much. Return on invested capital (ROIC) measures how effectively a company generates operating profit from its raised capital.

While Boston Scientific has recently shown solid fundamentals, its historical investment in growth initiatives has been less impressive. The company’s five-year average ROIC was 6.7%, which is modest compared to leading healthcare firms that consistently deliver ROIC above 20%.

Conclusion

Boston Scientific’s strengths outweigh its weaknesses. After the recent drop, the stock is trading at a forward P/E of 22.2 (or $76.39 per share). Should you consider buying now?

Top Stocks That Outperform Boston Scientific

Discover Our Top 9 Market-Beating Stocks—these companies consistently surpass market expectations with strong revenue growth, rising free cash flow, and exceptional returns on capital. The market has already recognized their achievements.

Our AI-driven platform predicts continued success for these stocks. Find out which nine companies made the list this week—absolutely free.

Our selections include well-known names like Nvidia, which soared 1,326% from June 2020 to June 2025, and lesser-known companies such as Exlservice, which delivered a 354% five-year return.